OBJECTIVE: To investigate the clinical significance of lymphoid neogenesis (LN) in rheumatoid arthritis (RA), the clinicopathological correlates of this process and its evolution after anti-tumour necrosis factor (TNF)alpha therapy in a large series of synovial tissues were analysed. METHODS: Arthroscopic synovial biopsies from 86 patients with RA were analysed by immunohistochemistry. LN was defined as the presence of large aggregates of lymphocytes with T/B cell compartmentalisation and peripheral node addressin (PNAd) positive high endothelial venules. Clinical variables at baseline and after prospective follow-up were compared in LN positive and negative RA subsets. The evolution of LN and its correlation with the clinical course in a subgroup of 24 patients that underwent a second arthroscopic biopsy after anti-TNFalpha therapy was also analysed. RESULTS: LN was present in 49% of RA synovial tissues. Patients with LN had a significantly higher disease duration and a higher previous use of anti-TNFalpha agents. During prospective follow-up, the proportion of patients achieving good or moderate European League Against Rheumatism (EULAR) 28-joint Disease Activity Score (DAS28) responses was significantly lower in patients who were LN positive despite a significantly higher use of anti-TNFalpha agents. By multivariate logistic regression analysis, LN remained as an independent negative predictor of response to therapy. In the subgroup of patients rebiopsied after anti-TNFalpha therapy, reversal of LN features occurred in 56% of the patients and correlated with good clinical responses. CONCLUSIONS: Synovial LN in RA predicts a lower response to therapy. LN features can be reversed after a short period of anti-TNFalpha therapy in parallel to good clinical responses.
OBJECTIVE: To investigate the clinical significance of lymphoid neogenesis (LN) in rheumatoid arthritis (RA), the clinicopathological correlates of this process and its evolution after anti-tumour necrosis factor (TNF)alpha therapy in a large series of synovial tissues were analysed. METHODS: Arthroscopic synovial biopsies from 86 patients with RA were analysed by immunohistochemistry. LN was defined as the presence of large aggregates of lymphocytes with T/B cell compartmentalisation and peripheral node addressin (PNAd) positive high endothelial venules. Clinical variables at baseline and after prospective follow-up were compared in LN positive and negative RA subsets. The evolution of LN and its correlation with the clinical course in a subgroup of 24 patients that underwent a second arthroscopic biopsy after anti-TNFalpha therapy was also analysed. RESULTS: LN was present in 49% of RA synovial tissues. Patients with LN had a significantly higher disease duration and a higher previous use of anti-TNFalpha agents. During prospective follow-up, the proportion of patients achieving good or moderate European League Against Rheumatism (EULAR) 28-joint Disease Activity Score (DAS28) responses was significantly lower in patients who were LN positive despite a significantly higher use of anti-TNFalpha agents. By multivariate logistic regression analysis, LN remained as an independent negative predictor of response to therapy. In the subgroup of patients rebiopsied after anti-TNFalpha therapy, reversal of LN features occurred in 56% of the patients and correlated with good clinical responses. CONCLUSIONS: Synovial LN in RA predicts a lower response to therapy. LN features can be reversed after a short period of anti-TNFalpha therapy in parallel to good clinical responses.
Authors: C S Horjus Talabur Horje; C Smids; J W R Meijer; M J Groenen; M K Rijnders; E G van Lochem; P J Wahab Journal: Clin Exp Immunol Date: 2017-01-31 Impact factor: 4.330
Authors: Jixiang Shi; Qianqian Liang; Michael Zuscik; Jie Shen; Di Chen; Hao Xu; Yong-Jun Wang; Yan Chen; Ronald W Wood; Jia Li; Brendan F Boyce; Lianping Xing Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995
Authors: Frances Humby; Michele Bombardieri; Antonio Manzo; Stephen Kelly; Mark C Blades; Bruce Kirkham; Jo Spencer; Costantino Pitzalis Journal: PLoS Med Date: 2009-01-13 Impact factor: 11.069
Authors: Elena Izquierdo; Juan D Cañete; Raquel Celis; Begoña Santiago; Alicia Usategui; Raimon Sanmartí; Manuel J Del Rey; José L Pablos Journal: PLoS One Date: 2009-12-02 Impact factor: 3.240
Authors: M Margarida Souto-Carneiro; Vijayabhanu Mahadevan; Kazuki Takada; Ruth Fritsch-Stork; Toshihiro Nanki; Margaret Brown; Thomas A Fleisher; Mildred Wilson; Raphaela Goldbach-Mansky; Peter E Lipsky Journal: Arthritis Res Ther Date: 2009-06-05 Impact factor: 5.156